Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide

Rhea-AI Summary

Labcorp (NYSE: LH) expanded its collaboration with PathAI to deploy AISight Dx, an FDA-cleared digital pathology platform, across Labcorp's national anatomic pathology labs and hospital collaborations on Feb. 23, 2026. The cloud-based system enables fully digital workflows, AI-powered image analysis, secure storage and connectivity.

According to the company, deployment aims to scale digital slide review, improve turnaround times, enhance collaboration and support Labcorp's precision medicine products, building on a 2019 strategic investment in PathAI and prior AI-driven clinical trial support.

Positive

• FDA-cleared platform (AISight Dx) deployed nationwide
• Scales digital workflows across Labcorp's anatomic pathology labs
• Supports precision medicine and AI-driven clinical trial capabilities

Negative

• None.

News Market Reaction – LH

+0.93%

1 alert

+0.93% News Effect

On the day this news was published, LH gained 0.93%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $287.13 Vol: Volume 1,110,367 versus 2...

normal vol

$287.13 Last Close

Volume Volume 1,110,367 versus 20-day average 776,841, with relative volume at 1.43x ahead of the partnership news. normal

Technical Shares at $282.67 trade above the 200-day MA of $264.55 and about 3.76% below the 52-week high of $293.72.

Peers on Argus

LH was modestly up pre‑news (0.07%) while close peers were mixed: DGX (-0.95%), ...

LH was modestly up pre‑news (0.07%) while close peers were mixed: DGX (-0.95%), NTRA (-1.96%), IQV (-1.59%) versus MTD (+0.70%) and WAT (+1.93%). This points to a stock‑specific narrative.

Previous Partnership Reports

2 past events · Latest: Sep 30 (Positive)

Same Type Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Sep 30	Digital pathology deal	Positive	+1.5%	Strategic collaboration with Roche to deploy FDA‑cleared digital pathology scanners.
Mar 05	Fertility partnership	Positive	-1.4%	Partnership with Pinnacle Fertility to enhance genetic testing services.

Pattern Detected

Partnership headlines have produced small, mixed reactions, with one positive and one negative move and an average change of about 0.08%.

Recent Company History

Over the past two years, Labcorp has used partnerships to expand capabilities. A Sep 30, 2025 collaboration with Roche advanced FDA‑cleared digital pathology scanners and highlighted a projected shortage of 5,700 pathologists by 2030, yielding a +1.52% move. A Mar 5, 2024 fertility partnership produced a -1.35% reaction. Today’s PathAI collaboration extends this digital pathology and AI strategy across Labcorp’s national network, consistent with that partnership‑driven trajectory.

Historical Comparison

+0.1% avg move · In the last two partnership announcements, LH’s average move was about 0.08%, with one gain and one ...

partnership

+0.1%

Average Historical Move partnership

In the last two partnership announcements, LH’s average move was about 0.08%, with one gain and one decline. Today’s AI‑driven PathAI expansion fits this ongoing collaboration theme in digital and specialty testing.

Partnerships progressed from a 2024 fertility testing collaboration to a 2025 Roche digital pathology deal, and now to a 2026 PathAI deployment, broadening Labcorp’s AI‑enabled and digital pathology ecosystem.

Market Pulse Summary

This announcement expands Labcorp’s AI‑enabled digital pathology infrastructure via nationwide deplo...

Analysis

This announcement expands Labcorp’s AI‑enabled digital pathology infrastructure via nationwide deployment of the FDA‑cleared AISight Dx platform. It builds on a history of strategic partnerships in diagnostics and digital pathology, reinforcing a long‑term shift toward cloud‑based, fully digital workflows. Investors may focus on adoption within Labcorp’s anatomic pathology labs and hospital collaborations, the impact on efficiency and turnaround times, and how these capabilities support its broader precision medicine portfolio.

Key Terms

fda-cleared, digital pathology, ai-enabled, anatomic pathology, +2 more

6 terms

fda-cleared regulatory

"deploy AISight® Dx1, an FDA-cleared digital pathology platform, across its"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

digital pathology medical

"FDA-cleared digital pathology platform, across its national network of anatomic"

Digital pathology is the process of converting traditional microscope slides into high-resolution digital images and using software, cloud systems, and sometimes AI to view, analyze, store and share those images. It matters to investors because it can speed diagnosis, enable remote consultations, reduce laboratory bottlenecks and create software-driven services and recurring revenue—like the shift from film to digital photography, unlocking scale, efficiency and new monetization opportunities in healthcare.

ai-enabled technical

"support fully digital workflows and AI-enabled insights across Labcorp's network"

AI-enabled describes a product, service, or process that uses artificial intelligence—software that learns from data and makes decisions or predictions—as a core feature rather than a minor add-on. For investors it matters because AI-enabled offerings can boost productivity, lower costs or unlock new revenue streams; like adding a smart autopilot to a routine task, they can change a company's growth potential and competitive edge while also bringing higher upfront investment needs and distinct regulatory or ethical risks.

anatomic pathology medical

"across its national network of anatomic pathology labs and hospital collaborations."

Anatomic pathology is the medical specialty that identifies disease by examining organs, tissues and cells removed from the body — using microscopes, stains and other laboratory techniques much like a detective examining physical clues. For investors, it matters because those laboratory diagnoses drive clinical decisions, drug and device approvals, lab testing demand and payment, so the quality, volume and regulation of pathology services can directly affect revenue and regulatory risk across healthcare and diagnostics businesses.

precision medicine medical

"Labcorp will also incorporate digital pathology workflows in support of its precision medicine products."

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

cloud-based technical

"The cloud-based technology allows pathologists to view and manage slides"

Software, data or services that run on remote computers accessed over the internet instead of on a user’s own device; think of renting storage, apps and computing power in someone else’s warehouse rather than buying and maintaining the gear yourself. Investors care because cloud-based models can lower a company’s upfront costs, speed product updates, scale quickly with demand and create recurring revenue, all of which affect cash flow, growth prospects and valuation.

AI-generated analysis. Not financial advice.

AISight® Dx will support fully digital workflows and AI-enabled insights across Labcorp's network of anatomic pathology labs and hospital collaborations to improve efficiency, collaboration and patient care

BURLINGTON, N.C., Feb. 23, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with PathAI to deploy AISight® Dx¹, an FDA-cleared digital pathology platform, across its national network of anatomic pathology labs and hospital collaborations. The cloud-based technology allows pathologists to view and manage slides digitally and use AI to support key steps in the diagnostic process.

"Labcorp is committed to building a modern, AI-powered infrastructure that sets a new standard for efficiency, collaboration and innovation in pathology," said Dr. Marcia Eisenberg, chief scientific officer at Labcorp. "PathAI's technology allows us to scale digital pathology nationwide and integrate AI insights into routine care—delivering faster, more consistent results for patients and providers."

Labcorp will deploy AISight Dx across its anatomic pathology labs and hospital collaborations, enabling fully digital workflows for case management, slide review, collaboration and annotation. The platform also integrates AI-powered image analysis, secure storage and system connectivity to deliver faster turnaround, greater efficiency, reliable quality and improved collaboration. Labcorp will also incorporate digital pathology workflows in support of its precision medicine products.

"Labcorp's leadership in diagnostics makes them an ideal partner in our mission to modernize pathology through software and AI," said Dr. Andy Beck, co-founder and CEO of PathAI. "The deployment of AISight Dx across Labcorp's network brings high-quality, efficient digital pathology to a national scale."

The expansion builds on Labcorp's 2019 strategic investment in PathAI, a collaboration that has since advanced to include AI-driven clinical trial support and validation of novel AI-pathology solutions.

To learn more about Labcorp's digital pathology capabilities, visit https://www.labcorp.com/disciplines/digital-pathology-and-artificial-intelligence-ai

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

¹ AISight® Dx is FDA-cleared for primary diagnosis in the US and CE-IVD marked for primary diagnosis in the EEA, UK, and Switzerland.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the expected deployment and benefits of the Path AI AISight Dx digital pathology platform.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.

The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-expands-collaboration-with-pathai-to-deploy-fda-cleared-digital-pathology-platform-nationwide-302694248.html

SOURCE Labcorp

FAQ

What is Labcorp announcing about AISight Dx (LH) on Feb. 23, 2026?

Labcorp announced an expanded deployment of AISight Dx across its national anatomic pathology labs, scaling digital pathology nationwide. According to the company, the FDA-cleared platform enables digital slide review, AI image analysis, secure storage and connectivity to improve turnaround and collaboration.

How will the AISight Dx deployment affect Labcorp (LH) pathology workflows?

The deployment enables fully digital workflows for case management, slide review, collaboration and annotation at Labcorp labs. According to the company, the cloud-based system integrates AI-powered analysis and secure storage to deliver faster turnaround, greater efficiency and more consistent results.

Does Labcorp (LH) say AISight Dx is FDA-cleared and what does that mean?

Yes—AISight Dx is described as FDA-cleared and ready for clinical deployment across Labcorp's network. According to the company, FDA clearance supports clinical use while the platform adds AI-driven image analysis and connectivity for routine diagnostic workflows.

How does the PathAI partnership relate to Labcorp's precision medicine products (LH)?

Labcorp will incorporate digital pathology workflows to support its precision medicine products and trials. According to the company, the expanded PathAI deployment builds on a 2019 strategic investment and prior AI-driven clinical trial support and validation efforts.

What operational benefits does Labcorp (LH) claim from deploying PathAI's AISight Dx?

Labcorp cites faster turnaround, improved efficiency, reliable quality and enhanced collaboration across labs and hospitals. According to the company, the cloud-based platform and AI-powered analysis aim to standardize slide review and support clinical and research workflows nationwide.